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Abstract
Background: The purpose of this study is to analyze the combined effects of selected p53 and p73
polymorphisms and their interaction with lifestyle habits on squamous cell carcinoma of the head
and neck (SCCHN) risk and progression in an Italian population.
Methods: Two hundred and eighty-three cases and 295 hospital controls were genotyped for p53
polymorphisms on exon 4 (Arg72Pro), intron 3 and 6, and p73 G4C14-to-A4T14. Their association
with SCCHN was estimated using a logistic regression analysis, while a multinomial logistic
regression approach was applied to calculate the effect of the selected polymorphisms on SCCHN
different sites (oral cavity, oropharynx, hypopharynx and larynx). We performed an haplotype
analysis of the p53 polymorphisms, and a gene-gene interaction analysis for the combined effects
of p73 G4C14-to-A4T14 and p53 polymorphisms.
Results: We found a significant increased risk of SCCHN among individuals with combined p73
exon 2 G4A and p53 intron 3 variant alleles (OR = 2.22, 95% CI: 1.08–4.56), and a protective effect
for those carrying the p53 exon 4-p53 intron 6 diplotype combination (OR = 0.67; 95% CI: 0.47–
0.92). From the gene-environment interaction analysis we found that individuals aged < 45 years
carrying p73 exon 2 G4A variant allele have a 12.85-increased risk of SCCHN (95% CI: 2.10–78.74)
compared with persons of the same age with the homozygous wild type genotype. Improved
survival rate was observed among p53 intron 6 variant allele carriers (Hazard Ratio = 0.51 (95% CI:
0.23–1.16).
Conclusion: Our study provides for the first time evidence that individuals carrying p53 exon 4
and p53 intron 6 variant alleles are significantly protected against SCCHN, and also shows that an
additional risk is conferred by the combination of p73 exon 2 G4C14-to-A4T14 and p53 intron 3
variant allele. Larger studies are required to confirm these findings.
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Background
Squamous cell carcinoma of the head and neck (SCCHN),
including cancers of the oral cavity, pharynx and larynx, is
one of the five most common cancers worldwide [1]. Epi-
demiological studies suggest a multifactorial aetiology,
with smoking, alcohol drinking [2,3], oral HPV infection
[4], low fruit and vegetables intake [5,6], and genetic fac-
tors playing a major role [7].
The p53 protein, encoded by p53 tumor suppressor gene
(17p13), is involved in cell-cycle regulation, DNA repair,
inhibition of spontaneous mutations, and cellular differ-
entiation and apoptosis [8]. The p53 gene is highly poly-
morphic, with at least 13 different polymorphisms
described [9,10]. Some studies reported that rare p53 exon
4 – intron 3 – intron 6 haplotypes affect the frequency of
mutation and loss of heterozygosity in B-lymphoblastoid
cell lines, along with DNA repair and apoptosis [11,12].
Currently p53 exon 4 Arg72Pro polymorphism is the only
p53 single nucleotide polymorphism (SNP) whose effect
has been studied in relation to SCCHN, with conflicting
results. Three studies conducted on Caucasians [13-15]
reported the absence of a significant relationship between
Pro variant allele and SCCHN, while Tsai et al [16] sug-
gested an increased cancer risk for individuals carrying the
variant allele in a Chinese population. Two intronic poly-
morphisms of p53 consisting of a 16-bp duplication in
intron 3 and a G-A transition in intron 6, have been inves-
tigated in relation to lung, ovarian, breast and colon can-
cer, again with conflicting results [12,17-19]. To our
knowledge, no one study thus far has investigated the
effect of these two SNPs on SCCHN.
The p73 protein is a p53 homologue encoded by a poly-
morphic gene located on 1p36-33, mapping on a region
often deleted in a variety of human cancers [20,21]. p73
protein activates several p53-responsive genes involved in
cell cycle control, DNA repair and apoptosis, and inhibits
cell growth in a p53-like manner by inducing apoptosis
[22]. A p73 G4C14-to-A4T14 dinucleotide polymorphism
has been reported to influence gene expression, and con-
sists of two SNPs in complete linkage disequilibrium at
positions 4 (G-A) and 14 (C-T) in the non-coding region
of exon 2 [23]. Several studies investigated the relation-
ship between the p73 G4C14-to-A4T14 polymorphism
and cancer [10,24-27], among them the large study con-
ducted by Li et al. reported an increased risk for SCCHN
in Caucasians carrying the p73 G4C14-to-A4T14 variant
genotype compared to GC/GC [10].
To our knowledge, no one study investigated the influ-
ence of p53 intron 3 and 6 polymorphisms on SCCHN
survival, while a poor disease-free survival has been
reported in patients carrying the p53 exon4 Arg72Pro var-
iant on SCCHN, lung, colorectal and breast cancer [28-
31]. Lastly, a study reports an improved survival of color-
ectal cancer patients carrying the variant allele of p73
G4C14-to-A4T14 [32].
The purpose of our study was to investigate the effects of
p73 G4C14-to-A4T14 polymorphism and three p53-SNPs
in exon 4 and introns 3 and 6, as well as their combina-
tion and their interaction with lifestyle habits, in associa-
tion with SCCHN risk and progression within a hospital-
based case-control study in an Italian population.
Methods
Study Population
The study subjects were added to the age and gender
matched sample of the previously published case-control
study [5]. Study participants were recruited from among
patients admitted to the teaching hospital "A. Gemelli" of
the Università Cattolica del Sacro Cuore (Rome, Italy)
during the time period from May 2002 to May 2007, and
eligibility was restricted to Caucasian individuals born in
Italy. Cases were consecutive primary untreated head and
neck cancer patients admitted to the Department of
Otorhinolaryngology with histologically-confirmed squa-
mous cell carcinoma of the head and neck (SCCHN).
SCCHN diagnosis was defined according to the Interna-
tional Classification of Disease (9th revision, codes 140–
149 and 161). Tumors were staged according to the UICC-
TNM classification; 48.9% were staged I-II and 53.9%
were classified T1-T2 (tumor stage was missing for one
patient, and tumor grade was missing for one patient)
[33]. Cases presented the following distribution according
to tumor site: 67.7% laryngeal, 18.6% oral cavity, 6.5%
oropharyngeal, and 8.2% hypopharyngeal. Controls were
selected from among cancer-free patients admitted to the
same hospital during the same time period with a broad
range of diagnoses without matching to cases by any cov-
ariate. The study sample size comprised 283 cases and 295
controls, with a participation rate of 98% among cases
and 93% among controls. Written informed consent was
obtained from all study subjects, after which each subject
provided a venous blood sample that was collected into
EDTA-coated tubes. This study was performed according
to the Declaration of Helsinki and was approved by the
ethics committee of the Università Cattolica del Sacro
Cuore.
Genotyping
Genotyping for p53 intron 3 (rs17883323), p53 exon 4
codon 72 (rs1042522) and p53 intron 6 (rs1625895) pol-
ymorphisms were performed using a polymerase chain
reaction (PCR) followed by restriction-fragment length
polymorphism, as already described by Wu et al [12].
Genotyping of p73 exon 2 (rs2273953-rs1801173) was
determined using DNA amplification, conducted as
described by Niwa et al [25]. We conducted haplotypeBMC Cancer 2009, 9:137 http://www.biomedcentral.com/1471-2407/9/137
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analysis for p53 intron 3, p53 exon 4 codon 72 and p53
intron 6 polymorphisms using EH software [34] and
cocaphase [35]. Quality control for each genotyping was
performed in each experiment, and 10% of the total sam-
ples were randomly selected and retested with 100% con-
cordance. The analyst was blinded to the case or control
status of the samples.
Data Collection
A standard questionnaire was administered to cases and
controls by trained medical doctors to elicit information
on demographic variables, including cigarette smoking,
drinking history, fruit and vegetable intake, physical activ-
ity, family history of cancer, and family history of SCCHN
specifically. Participants were asked to focus on the year
prior to diagnosis (for controls the year prior to the inter-
view date) when answering questions regarding lifestyle.
Pack-years were calculated as years smoked multiplied by
the current number (or previous number, for those who
had quit) of cigarettes smoked/day divided by 20. For
quantification of fruit and vegetable intake, 70 grams was
considered an average portion of vegetables (both fresh
and cooked vegetables included) and 100 grams was con-
sidered an average portion of fruit [36]. Participants were
classified as consuming ≥ 2 portions/day if they regularly
consumed at least one portion of fruit and one portion of
vegetables per day or if they consumed at least 2 portions
of fruit or 2 portions of vegetables per day. Cases were fol-
lowed-up after histopathological diagnosis of cancer with
a median follow-up time of 23 months (range 1–60
months), and information on recurrence of local and/or
regional neck nodes was also recorded. Data concerning
previous Human Papilloma Virus (HPV) infection were
not available for either cases or controls as well as treat-
ment practices adopted by cases.
The proportion lost to follow-up among cases in the study
cohort was 6.0%. The response rate for interview comple-
tion was 98.0% among cases and 96.0% among controls,
with the exception of data relating to the family history of
cancer (unknown in 22% of cases and 3.4% of controls),
as well as the family history of oral cancer (unknown in
28.7% of cases and 3.4% of controls).
Statistical analysis
The relationship between SCCHN and putative risk fac-
tors were measured using the adjusted odds ratios (ORs)
and their 95% confidence intervals (CI) derived from
logistic regression analysis using STATA software (version
9). The SCCHN risk according to the 4 studied polymor-
phisms was estimated under the dominant model (variant
allele carriers versus  wild type allele homozygous). We
considered possible risk factors for SCCHN as potential
confounders if addition of that variable to the model
changed the OR by 10% or more. Confounding checks
were performed in both univariate and final multivariate
models. If a factor was identified as a confounder of any
estimated main effect, it was kept in all models. Based on
these criteria, we controlled for gender, alcohol, pack-
years of cigarette smoking, physical activity and fruit and
vegetable intake. With exception of gender, we adjusted
for confounders as continuous variables. After a logistic
regression model has been fitted, the Hosmer-Lemeshow
test was performed to assess the goodness of the model.
We tested the relationship between the analyzed polymor-
phisms and tumour location (oral cavity, oropharynx,
hypopharynx and larynx cancer) [3] by using a logistic
multinomial regression analysis, using healthy controls as
the reference group.
The False Discovery Rate (FDR), which controls the
expected proportion of false positives among a threshold
given by the observed p-value distribution [37], was per-
formed to correct for multiple comparisons resulting from
association between the four polymorphisms and the dif-
ferent tumour locations.
Tests of Hardy Weinberg Equilibrium (HWE) were carried
out for all of the polymorphisms among cases and con-
trols separately http://ihg.gsf.de/cgi-bin/hw/hwa1.pl. In
order to examine if the effects of the studied polymor-
phisms are modified by selected environmental exposures
and some other covariates, we performed a logistic regres-
sion analysis stratified by age, gender, alcohol, smoking
status and family history of cancer. An homogeneity test
was then used to test differences among the strata. In this
analysis we used as a reference group those homozygous
wild-type individuals who had not been exposed and con-
founders were considered as follows: age was categorized
into ≤ 45 and > 45 years old [38], smoking status was con-
sidered as ever/never cigarette smokers, and alcohol con-
sumption as drinkers/non-drinkers (the latter including
individuals whose alcohol intake was less than 7 g/day).
A gene-gene interaction analysis was performed among
p73 G4C14-to-A4T14 polymorphism and three p53-SNPs
in exon 4 and introns 3 and 6, and the likelihood ratio test
was used to test for more than multiplicative effect among
each pair of SNPs, with the homozygous wild-type indi-
viduals used as the reference group for each gene.
Overall survival curves were calculated by the Kaplan-
Meier product limit method from the date of diagnosis
until progression of disease or death. If a patient was not
dead, survival was censored at the time of the last visit.
The log rank test was used to assess differences between
subgroups. Disease Free Survival (DFS) was calculated
from the day of histological diagnosis to the date of local
recurrence of disease and/or regional lymph-node
involvement. The risk of death and the risk of recurrenceBMC Cancer 2009, 9:137 http://www.biomedcentral.com/1471-2407/9/137
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related to the studied polymorphisms were estimated by
Cox's proportional hazards model. Hazard ratios (HR)
were adjusted for age, gender, and stadium, with the wild-
type genotypes as the reference group.
Results
General characteristics of the study population are pre-
sented in Table 1. The percentage of males was higher in
cases then in controls (82.7% vs 60.0%; Table 1). Results
show that alcohol consumption increases head and neck
cancer risk, especially among heavy drinkers (OR = 18.56;
95% CI: 7.26–47.44). An increased risk was also detected
for cigarette smokers, with an OR of 2.97 (95% CI: 1.72–
5.12) and 8.23 (95% CI: 4.73–14.32) for 1–24 and > 24
pack-years of cigarettes smoked, respectively (Table 1). A
low consumption of fruit and vegetables (< 2 portions/
day) was significantly associated with SCCHN (OR = 2.70;
95% CI: 1.73–4.21). Additionally, family history of can-
cer was higher in cases than controls (OR = 2.42; 95% CI:
1.42–4.13), and even higher when considering the family
history of SCCHN, although this is limited to a very small
numbers of individuals (data not shown). Goodness of fit
statistics provided a p-value > 0.42.
The genotype frequencies of our control group were in
line with those of Caucasians [39,40] and were in HWE
for both cases and controls (p- value > 0.05). As shown in
Table 2, the distribution of the studied polymorphisms
was similar amongst the two groups. A significant associ-
ation was observed between p73 variant allele carriers and
cancer of the oral cavity (OR = 2.43; 95% CI: 1.23–4.81;
p-value = 0.01), even if it didn't remain noteworthy after
the FDR test correction because the statistically significant
threshold was set at p = 0.0002. The estimated p53 pair-
wise haplotype frequencies among the three polymor-
phisms and their linkage disequilibrium values in cases
and controls are shown in Table 3. The pairwise linkage
disequilibria were highly significant in both control and
patient population (p value for χ2 test < 0.001). The fre-
quency of exon 4 (Pro)/intron 6 diplotype was lower in
cases than in controls (12.1% versus 17.6%), with more
than 30% reduced risk of SCCHN (OR = 0.67; 95% CI:
0.47–0.92). There were no significant differences in the
remaining diplotype frequencies among cases and con-
trols (p value > 0.1, Table 3). When the estimation of hap-
lotype frequencies was extended to all the three SNPs
(Table 4), results showed no significant difference in the
haplotype frequencies among cancer patients and con-
trols (p value > 0.1). From the p73-p53 gene-gene interac-
tion analysis a more than additive effect was found for
those carrying both p53 intron 3 and p73 variant alleles,
with an OR of 2.22 (95% CI: 1.08–4.56) (Table 5) [41].
From our analysis there was no evidence of effect modifi-
cation of the four SNPs by the environmental exposures
(data not shown). Age was an effect modifier of the asso-
ciation between p73 exon 2 and SCCHN [OR = 12.85
(95% CI: 2.10–78.74) in individuals younger than 45
years versus an OR = 1.19 (95% CI: 0.72–1.96) in individ-
uals older than 45 years (p value of homogeneity among
Table 1: Odds Ratios (95% Confidence Interval) for squamous cell carcinoma of the head and neck (SCCHN) according to the 
collected variables.
283 Cases 295 Controls OR° (95% CI)
n (%) n (%)
Age (years ± SD) 63.3 ± 11.2 63.5 ± 13.1 -
Male gender 234 (82.7) 177 (60.0) 0.85 (0.50 – 1.42)
Alcohol drinkers
0 g/day 59 (20.9) 146 (49.7) 1*
1–30 g/day 119 (42.2) 141 (48.0) 1.58 (0.98 – 2.52)
> 31 g/day 104 (36.88) 7 (2.38) 18.56 (7.26 – 47.44)
Pack-years of smoking
0 58 (18.5) 179 (62.0) 1*
1–24 67 (23.8) 66 (22.8) 2.97 (1.72 – 5.12)
> 24 162 (57.7) 44 (15.2) 8.23 (4.73 – 14.32)
Fruit and vegetables intake
≥ 2 portions/day 116 (41.1) 198 (69.5) 1*
< 2 portion/day 166 (58.9) 87 (30.5) 2.70 (1.73 – 4.21)
Physical activity
≥ 2 times/week 15 (5.5) 30 (10.2) 1*
< 2 time/week 259 (94.5) 263 (89.8) 1.56 (0.68 – 3.57)
Family history of cancer
No 137 (62.0) 232 (81.4) 1*
Yes 84 (38.0) 53 (18.6) 2.42 (1.42 – 4.13)
* Reference group
° Odds Ratio (OR) adjusted for gender, alcohol, pack-years, physical activity and fruit and vegetables intakeBMC Cancer 2009, 9:137 http://www.biomedcentral.com/1471-2407/9/137
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Table 2: Odds Ratios (95% CI) for head and neck cancer according to the studied polymorphisms








OR° for larynx 
(186 cases)
N (%) N (%) (95% CI) (95% CI) (95% CI) (95% CI) (95% CI)
p53 intron 3
(rs1788332)
WW 191 (67.5) 209 (70.8) 1* 1* 1* 1* 1*
M carriers 92 (32.5) 86 (29.2) 1.30 
(0.81 – 2.10)




ArgArg 175 (61.85) 169 (57.3) 1* 1* 1* 1* 1*
Pro carriers 108 (38.2) 126 (42.7) 1.07 
(0.68 – 1.67)
1.02 (0.53 – 1.97) 1.66 (0.59 – 4.62) 0.87 (0.34 – 2.22) 0.91 (0.55 – 1.49)
p53 intron 6
(rs1625895)
GG 194 (68.5) 192 (65.1) 1* 1* 1* 1* 1*
C carriers 89 (31.5) 86 (34.9) 0.99 
(0.63 – 1.58)
0.49 (0.23 – 1.05) 1.28 (0.45 – 3.65) 0.70 (0.26 – 1.91) 1.00 (0.60 – 1.67)
p73 exon 2 G4A
(rs1801173/
rs2273953)
GC/GC 187 (66.1) 214 (72.5) 1* 1* 1* 1* 1*
AT carriers 96 (33.9) 81 (27.5) 1.51 
(0.94 – 2.43)
2.43 (1.23 – 
4.81)§
1.99 (0.69 – 5.69) 0.48 (0.13 – 1.71) 1.46 (0.86 – 2.46)
* Reference group
° OR adjusted for gender, alcohol, pack-years, physical activity and fruit and vegetables intake
§ This association (p-value = 0.01) didn't remain noteworthy after the FDR test correction because the statistically significant threshold was set at p-
value = 0.0002.
Table 3: Pairwise haplotype frequencies in SCCHN patients and controls.
No. alleles Estimated haplotype frequency D'
‡ 1 - 1 1 - 2^ 2 - 1 2 - 2
Intron 3-exon 4 †
Cases 566 0.740 0.052 0.086 0.120 0.61
Controls 590 0.716 0.030 0.120 0.131 0.74
Intron 3-intron 6†
Cases 566 0.772 0.055 0.058 0.115 0.61
Controls 590 0.763 0.074 0.035 0.128 0.73
Exon 4-intron 6*
Cases 566 0.744 0.049 0.086 0.121 0.64
Controls 590 0.719 0.026 0.076 0.176 0.83
† p-value of χ2-test: cases versus controls > 0.1
* p-value < 0.001
‡ 1 = intron 3 (W), exon 4 Arg, intron 6 G
^ 2 = intron (M), exon 4 Pro, intron 6 ABMC Cancer 2009, 9:137 http://www.biomedcentral.com/1471-2407/9/137
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the estimates = 0.013)]. In addition, current smokers car-
rying the variant allele of p73 exon 2 had an OR of 3.60
(95% CI: 1.30–9.92) for SCCHN, while never smokers an
OR of 1.32 (95% CI: 0.80 – 2.19; p value of heterogeneity
among strata estimates = 0.10). Lastly, female smokers
carrying the variant allele of p73 exon 2 had an OR of 4.18
(95% CI: 0.92–19.02) for SCCHN versus an OR of 1.07
(95% CI: 0.54–2.14) among smoker males (p value of
homogeneity = 0.10).
Overall actuarial 2-year survival rate was 84.4% (95% CI:
79.7–88.2) with a 2-year DFS rate of 81.2% (95% CI:
76.2–85.3). During the follow-up period local recurrence
was observed in 53 cases, among them five patients also
experienced metastatic regional lymph-node involve-
ment. The survival analysis showed no significant associ-
ation between any of the polymorphisms, overall survival
and DFS (data not shown), even though individuals car-
rying p53 intron 6 variant allele had an HR for the overall
survival of 0.51 (95% CI: 0.23–1.16) (p-value for log-rank
test = 0.05) (Figure 1).
Discussion
This case-control study evaluated the effect of four poly-
morphisms in the p53 and p73 genes on the risk of squa-
mous cell carcinoma of the head and neck in an Italian
population. To our knowledge, our's is the first study
reporting an increased risk of SCCHN among individuals
with combined p73 exon 2 G4A and p53 intron 6 variant
alleles and a protective effect for those carrying p53 exon
4- p53 intron 6 diplotype combination. Additionally, we
showed that p73 exon 2 G4A variant allele increases the
risk of cancer of the oral cavity, which is in line with the
results of Li et al [10]. From the gene-environment inter-
action analysis we showed that individuals aged < 45
years carrying p73 exon 2 G4A variant allele have 12.85-
times significant increased risk for SCCHN compared with
persons of the same age with the homozygous wild type
genotype. Even though this observation stems from a sub-
group made up of less than 100 individuals, it confirms
the results of Li et al [10]. The absence of an association
between p53 exon 4 and SCCHN confirms the results of
three published studies among Caucasians [13-15], while
the absence of a significant association between p53
introns 3 and 6 and SCCHN is in line with the results of
other tumour sites [42,43]. Lastly, carriers of the variant
allele of p53 intron 6 showed a poorer prognosis follow-
ing cancer diagnosis.
In interpretation of our results some limitations of the
study should be taken into account. Firstly, given the
results of our a posterior power calculation on the basis of
the prevalence of the analyzed polymorphisms in our
control population, our study is powered to detect a min-
imum OR of 2.0 for the effect of variant allele carriers for
all studied polymorphisms (with a significance level of
5%). The study's sample size limits the possibility to
explore the combined effects of the genotypes, or gene-
environment interactions, thus we need to increase the
sample size in order to confirm our results. However,
Table 4: Estimated p53 haplotype frequencies in SCCHN patients and controls.
Alleles ‡1 - 1 - 1 1 - 1 - 2^ 1 - 2 - 1 1 - 2 - 2 2 - 1 - 1 2 - 1 - 2 2 - 2 - 1 2 - 2 - 2
Intr 3-ex 4-intr 6
Cases 566 0.705 0.034 0.067 0.120 0.040 0.014 0.019 0.101
Controls 590 0.696 0.020 0.068 0.053 0.026 0.005 0.008 0.123
p-value of χ2-test: cases versus controls > 0.1
‡ 1 = intron 3 (W), exon 4 Arg, intron 6 G
^ 2 = intron (M), exon 4 Pro, intron 6 A
Table 5: Adjusted Odds Ratios (95% CI) of SCCHN for the p73 exon 2 G4A- p53 interaction analysis.
p53 intron 3 (rs1788332) p53 intron 6 (rs1625895) p53 exon4 Arg72Pro (rs1042522)
wt/wt mt carriers wt/wt mt carriers wt/wt mt carriers
wt/wt 1* 1.05 (0.57–1.91) 1* 0.94 (0.53–1.68) 1* 0.92 (0.53–1.61)
cases/controls 136/152 51/62 137/140 50/74 129/124 58/90
p73 exon 2 G4A mt carriers 1.25 (0.70–2.25) 2.22 (1.08–4.56) 1.49 (0.82–2.70) 1.50 (0.75–3.02) 1.33 (0.69–2.55) 1.63 (0.86–3.11)
(rs1801173/
rs2273953)
cases/controls 56/56 40/24 57/51 39/29 45/44 51/36
p for interaction† = 0.30 p for interaction† = 0.89 p for interaction† = 0.55
* = Reference category
† = By likelihood ratio testBMC Cancer 2009, 9:137 http://www.biomedcentral.com/1471-2407/9/137
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when appropriately conducted, large and small studies
should theoretically give the same results, but with a more
precise effect measure estimate in the larger ones [44]. Sec-
ondly, as in all case-control studies, information bias may
exist, leading to biased ORs of the effects of lifestyle and
environmental exposures, alone or in combination with a
gene polymorphism. Thirdly, data on HPV infection were
unavailable in our study population.
Our study reports for the first time an increased risk of
SCCHN in individuals carrying both p73 exon 2 and p53
intron 3 unfavourable variants. Taking into account all
the possible combinations of p73 exon 2 and p53 intron 3
alleles, the large study Schabath et al. [22] recently
reported a 13% increased risk of lung cancer for individu-
als carrying every additional variant allele, however they
did not differentiate among variant alleles. We did not
report any effect for the remaining p73-p53 gene-gene
interactions, thus confirming the results from Niwa et al
on p73 exon 2-p53 exon 2 and endometrial cancer [25].
The results of the p53 haplotype analysis and SCCHN
show that individuals carrying combined unfavourable
variants of p53 exon 4 and intron 6 are protected from
SCCHN, and these results are in line with those reported
for lung, breast and gastric cancer [12,45,46]. Due the
potential application of these results in cancer prevention,
additional in vitro studies are urgently required to clarify
the mechanism through which the combined effect of
these strongly linked p53 SNPs might influence the pro-
tein function.
Our study shows that p73 exon 2 G4C14-to-A4T14 poly-
morphism increases the risk of cancer of the oral cavity,
even though the result is no longer significant after correc-
tion for multiple testing. This is in line, however, with
results from Li et al [10], and for other tumour sites such
as colorectal, oesophageal, and gastric cancer among Cau-
casians [10,24,32]. Additionally, p73 exon 2 G4C14-to-
A4T14 polymorphism seems to increase the risk of
SCCHN particularly among individuals younger than 45,
where the genetic susceptibility usually plays a major role
in the early onset of SCCHN with respect to the environ-
mental exposures [24]. Lastly, gender appears to be an
effect modifier of the association between p73 AT variant
allele and SCCHN, with female smokers at an increased
risk compared to males, as reported from Li et al. [10].
Association between p 53 intron 6 and overall survival among 283 SCCHN cases Figure 1
Association between p 53 intron 6 and overall survival among 283 SCCHN cases.BMC Cancer 2009, 9:137 http://www.biomedcentral.com/1471-2407/9/137
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Based on previous findings showing that women tend to
have a lower capacity of DNA repair with respect to men
[26], it is possible that women carrying the p73 G4C14-to-
A4T14 variant allele are more sensitive to carcinogens. In
order to confirm the potential role of the p73 G4C14-to-
A4T14 polymorphism on SCCHN, however, further stud-
ies on its functional effect are needed. Since this polymor-
phic site is located in a non coding region it remains to be
explained how the variant allele can modulate the protein
function. Also, it should be verified that p73 G4C14-to-
A4T14 does not exists in linkage disequilibrium with
functional alleles at other susceptibility loci [24].
The results of the present study shows a decreased mortal-
ity rate for individuals carrying the variant allele of p53
intron 6 compared with the wild-type genotype. A similar
result has been reported for the intestinal histotype of gas-
tric cancer (De Feo et al. A case-control study on the effect
of p53 and p73 polymorphisms on gastric cancer risk and
progression in an Italian population. 'Mutation Research,
Genetic Toxicology and Environmental Mutagenesis', in
press) and chronic lymphocitic leukaemia patients when
considering the time of treatment-free survival as the
main outcome [45]. Due to the small number of people
involved in the survival anlaysis, however, further
research should confirm our preliminary evidence.
Conclusion
Our study provides for the first time evidence that individ-
uals carrying both p53 exon 4 and p53 intron 6 variant
allels are significantly protected against SCCHN, while an
additional risk is conferred by the combination of p73
exon 2 G4C14-to-A4T14 and p53 intron 3 variant alleles.
We confirm the existing evidence that p73 exon 2 G4C14-
to-A4T14 increases the risk of oral cavity cancer. Larger
prospective studies are needed to further confirm our
results.
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